NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Booth RA, Ansari MT, Tricco AC, et al. Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Dec. (Evidence Reports/Technology Assessments, No. 196.)

Cover of Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs

Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs.

Show details

References and Included Studies

1.
Newman W, Payne K, Tricker K, Roberts S, Fargher E, Pushpakom S, Alder J, Sidgwick G, Payne D, Elliott R, et al. A pragmatic randomised controlled trial of thiopurine methyltransferase (TPMT) genotyping in the managment of patients, prior to azathioprine treatment: The TARGET study[Draft] 2010. Unpublished work. [PubMed: 21692613]
2.
Perillo M, Hannan M, Lemberg D. Advanced diagnostic imaging of adults with neck or low back pain: a seed algorithm. Topics in Clinical Chiropractic. 1997 Mar;4(1):9–14.
3.
Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Experiment Med Biol. 1999;455:343–8. [PubMed: 10599368]
4.
Parfrey PS, Hutchinson TA, Lowry RP, et al. The role of azathioprine reduction in late renal allograft failure. Transplantation. 1985 Feb;39(2):147–51. [PubMed: 3881853]
5.
Gheith OA, Bakr MA, Fouda MA, et al. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience. Clin Exp Nephrol. 2007 Jun;11(2):151–5. [PubMed: 17593515]
6.
Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006 Oct 14;368(9544):1339–48. [PubMed: 17046466]
7.
Eklund BI, Moberg M, Bergquist J, et al. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Molecular Pharmacol. 2006 Aug;70(2):747–54. [PubMed: 16717136]
8.
Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996 Aug 23;273(5278):1109–11. [PubMed: 8688098]
9.
Elion GB. The purine path to chemotherapy. Science. 1989 Apr 7;244(4900):41–7. [PubMed: 2649979]
10.
Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003 Apr;111(8):1133–45. [PMC free article: PMC152932] [PubMed: 12697733]
11.
Krynetski EY, Fessing MY, Yates CR, et al. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharmaceutical Research. 1997 Dec;14(12):1672–8. [PubMed: 9453052]
12.
Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet. 2000;45(5):299–302. [PubMed: 11043513]
13.
Lee D, Szumlanski C, Houtman J, et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metabol Dispos. 1995 Mar;23(3):398–405. [PubMed: 7628307]
14.
Ujiie S, Sasaki T, Mizugaki M, et al. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 - *24) Pharmacogenet Genomics. 2008 Oct;18(10):887–93. [PubMed: 18708949]
15.
Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A Review. Am J Gastroenterol. 2008;103(7):1783–800. [PubMed: 18557712]
16.
Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. [Review] [39 refs] Clin Exp Dermatol. 2001 Jul;26(5):369–75. [PubMed: 11488818]
17.
Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Molecul Genet. 1999 Feb;8(2):367–70. [PubMed: 9931345]
18.
Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999 Feb;9(1):37–42. [PubMed: 10208641]
19.
Efrati E, Adler L, Krivoy N, et al. Distribution of TPMT risk alleles for thioupurine toxicity in the Israeli population. Eur J Clin Pharmacol. 2009 Mar;65(3):257–62. [PubMed: 19048244]
20.
Weyer N, Kroplin T, Fricke L, et al. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol. 2001 May;57(2):129–36. [PubMed: 11417444]
21.
Kurzawski M, Gawronska-Szklarz B, Drozdzik M. Frequency distribution of thiopurine S-methyltransferase alleles in a polish population. Ther Drug Monit. 2004 Oct;26(5):541–5. [PubMed: 15385838]
22.
McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999 Dec;9(6):773–6. [PubMed: 10634140]
23.
Engen RM, Marsh S, Van Booven DJ, et al. Ethnic differences in pharmacogenetically relevant genes. [Review] [120 refs] Curr Drug Targets. 2006 Dec;7(12):1641–8. [PubMed: 17168839]
24.
Wang L, Pelleymounter L, Weinshilboum R, et al. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics. 2010 Jun;20(6):401–5. [PMC free article: PMC3086840] [PubMed: 20154640]
25.
Salavaggione OE, Wang L, Wiepert M, et al. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics. 2005 Nov;15(11):801–15. [PubMed: 16220112]
26.
Hamdan-Khalil R, Allorge D, Lo-Guidice JM, et al. In vitro characterization of four novel nonfunctional variants of the thiopurine S-methyltransferase. Biochem Biophys Res Commun. 2003 Oct 3;309(4):1005–10. [PubMed: 13679074]
27.
Kham SK, Soh CK, Aw DC, et al. TPMT*26 (208F-->L), a novel mutation detected in a Chinese. Br J Clin Pharmacol. 2009 Jul;68(1):120–3. [PMC free article: PMC2732947] [PubMed: 19660010]
28.
Feng Q, Vannaprasaht S, Peng Y, et al. Thiopurine S-methyltransferase pharmacogenetics: Functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol. 2010;79(7):1053–61. [PMC free article: PMC2815203] [PubMed: 19945438]
29.
Sasaki T, Goto E, Konno Y, et al. Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. Drug Metab Pharmacokinet. 2006 Aug;21(4):332–6. [PubMed: 16946561]
30.
Anstey AV, Wakelin S, Reynolds NJ, et al. Guidelines for prescribing azathioprine in dermatology. [Review] [54 refs] Br J Dermatol. 2004 Dec;151(6):1123–32. [PubMed: 15606506]
31.
Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterol. 2006 Mar;130(3):935–9. [PubMed: 16530531]
32.
U.S.Food and Drug Administration - Center for Drug Evaluation and Research. Overview: Imuran [website] [Last accessed: Dec 15 2009]. http://www​.accessdata​.fda.gov/scripts/cder/drugsatfda/index​.cfm.2009.
33.
Sampson M, McGowan J, Cogo E, et al. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009 Sep;62(9):944–52. [PubMed: 19230612]
34.
EPPI-Centre Software. EPPI-Reviewer 30: analysis and management of data for research synthesis [computer program] Social Science Research Unit, Institute of Education; 2006.
35.
Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003 Nov 10;3:25. [PMC free article: PMC305345] [PubMed: 14606960]
36.
Organization for Economic Co-Operation and Development. Purchasing Power Parities (PPP) [website] 2009. Available from: http://www​.oecd.org/department​/0,3355,en​_2649_34357_1_1_1_1_1,00.html. [updated 2009; cited 2009 May 15]
37.
U S Bureau of Labor Statistics. Databases, tables & calculators by subject [website] 2009. Available from: http://www​.bls.gov/data/#prices. [updated 2009; cited 2009 May 15]
38.
Minelli C, Thompson JR, Abrams KR, et al. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol. 2008 Feb;37(1):136–46. [PubMed: 18037675]
39.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010 May;63(5):513–23. [PubMed: 19595577]
40.
Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum. 1995 Mar;38(3):318–25. [PubMed: 7880185]
41.
The Netherlands Organisation for Health Research and Development (ZonMw) Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system (project) (Project record) The Netherlands Organisation for Health Research and Development (ZonMw); 2006.
42.
Sheffield LJ, Irving P, Gupta A, et al. Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. Pharmacogenomics. 2009 Jul;10(7):1091–9. [PubMed: 19604082]
43.
Barlow N. Is TPMT testing cost-effective? A study of the use of a national service for TPMT in relation to the health economic debate on pharmacogenomic testing. Pathology News. 2009;(May):1–4.
44.
Barlow N, Ford L, Berg J. Is TPMT testing cost-effective? A study of the use of a national service for TPMT in relation to the health economic debate on pharmacogenomic testing. Ann Clin Biochem. 2009;46(Suppl 1):91.
45.
Colletti RB, Baldassano RN, Milov DE, et al. Variation in care in pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2009 Sep;49(3):297–303. [PubMed: 19590456]
46.
Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Oct 15;28(8):973–83. [PubMed: 18616518]
47.
Palmieri O, Latiano A, Bossa F, et al. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy.[erratum appears in Aliment Pharmacol Ther. 2007 Sep 15;26(6):968] Aliment Pharmacol Ther. 2007 Sep 1;26(5):737–45. [PubMed: 17697207]
48.
Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Jan;13(1):57–64. [PubMed: 17206640]
49.
Lindqvist M, Hindorf U, Almer S, et al. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids. 2006;25(9–11):1033–7. [PubMed: 17065060]
50.
Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Jul 15;24(2):331–42. [PubMed: 16842460]
51.
Stocco G, Martelossi S, Barabino A, et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis. 2005 Dec;37(12):940–5. [PubMed: 16202677]
52.
von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.[erratum appears in Clin Chem. 2006 Aug;52(8):1628 Note: Schutz, Ekkehard [added]] Clin Chem. 2005 Dec;51(12):2282–8. [PubMed: 16214825]
53.
Okada Y, Nakamura K, Kodama T, et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol Pharm Bull. 2005 Nov;28(11):2117–9. [PubMed: 16272700]
54.
Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004 Jun;26(3):311–8. [PubMed: 15167634]
55.
Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004 May;2(5):410–7. [PubMed: 15118980]
56.
Marinaki AM, Arenas M, Khan ZH, et al. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics. 2003 Feb;13(2):97–105. [PubMed: 12563179]
57.
Corominas H, Domenech M, Laiz A, et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology. 2003 Jan;42(1):40–5. [PubMed: 12509611]
58.
Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther. 2002 Mar;16(3):389–98. [PubMed: 11876691]
59.
Stocco G, Martelossi S, Decorti G, et al. Pharmacogenetics of thiopurines: Can posology be guided by laboratory data. Radiol Oncol. 2004;38(2):101–9. +157.
60.
Colletti RB, Baldassano RN, Milov DE, et al. Variation in initial 6-mercaptopurine dosage in pediatric Crohn's disease. Gastroenterol. 2006;130
61.
van Dieren J, van Vuuren H, Kuipers E, et al. Heterozygous polymorphisms in the genes encoding ITPA and TPMT*3A are not predictive for the development of adverse effects of azathioprine treatment in IBD patients. Gastroenterol. 2005;128
62.
Ansari AR, Soon SY, Lindsay J, et al. Thiopurine methyl transferase activity predicts both toxicity and clinical response to azathioprine in inflammatory bowel disease: The London IBD forum prospective study. Gastroenterol. 2004;126
63.
Zelinkova Z, Derrijks L, Stokkers P, et al. Inosine triphosphate pyrophosphatase gene mutation predicts myelosuppression in IBD patients treated with azathioprine. Gastroenterol. 2004;126
64.
Hurlburt K, Mayo M, Yeo A, et al. TPMT activity related to azathioprine dosing and treatment of autoimmune hepatitis. Hepatology. 2005;42(4, Suppl 1):291A.
65.
Pageaux G, Masbou J, Brunschwig C, et al. Are hepatic toxic effects of thiopurine derivatives drugs related to thiopurine methyltransferase activity deficiency. Gastroenterol. 1997;112
66.
Wang L, Sullivan W, Toft D, et al. Thiopurine S-methyltransferase (TPMT) pharmacogenetics: Role of chaperone proteins in variant allozyme degradation. Clin Pharmacol Ther. 2003;73(2)
67.
Watanabe K, Simmons J, Orchard T, et al. Allelic variants of thiopurine methyl transferase are associated with azathioprine induced leukopaenia. Gut. 2000;46(11)
68.
Comer M, James I, D'Cruz D, et al. Erythrocyte thiopurine methyltransferase (TPMT) activity in rheumatoid arthritis patients experiencing azathioprine haematological toxicity. Br J Rheumatol. 1998;37
69.
Palmieri O, Latiano A, Bossa F, et al. Multiple genetic testing to explain intolerance to azathioprine. Gastroenterol. 2006;130
70.
Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.[see comment] Aliment Pharmacol Ther. 2007 May 1;25(9):1069–77. [PubMed: 17439508]
71.
Winter J, Gaffney D, Shapiro D, et al. Azathioprine tolerance in inflammatory bowel disease: Assess TPMT status by phenotype or genotype. Gut. 2007;56
72.
Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006 Dec;101(12):2769–76. [PubMed: 17026564]
73.
Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: Long-term follow-up study of 394 patients. Gastroenterol. 2007;132 [PubMed: 17026564]
74.
Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006 Oct;55(10):1423–31. [PMC free article: PMC1856436] [PubMed: 16543290]
75.
Hindorf U, Lindqvist M, Strom M, et al. Lack of association between the inosine triphosphate pyrophosphatase (ITPA) 94C > A polymorphism, the TPMT genotype, the baseline tpmt activity and adverse effects from thiopurine medication in inflammatory bowel disease. Gastroenterol. 2005;128
76.
Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol. 2006 Oct;45(4):584–91. [PubMed: 16876902]
77.
Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping and measurement of 6-thioguanine metabolites in the management of autoimmune hepatitis. Hepatology. 2003;38(4 Suppl 1):489A.
78.
Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of azathioprine-treated patients with inflammatory bowel disease. Gastroenterol. 2006;130 [PubMed: 16842460]
79.
Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci. 2006 May;51(5):968–75. [PubMed: 16773433]
80.
Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Hepatology. 2004;40(4, Suppl 1):418A.
81.
Gearry RB, Roberts RL, Barclay ML, et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 2004 Nov;14(11):779–81. [PubMed: 15564886]
82.
Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Aug 15;18(4):395–400. [PubMed: 12940924]
83.
Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.[see comment] Aliment Pharmacol Ther. 2004 Sep 15;20(6):593–9. [PubMed: 15352906]
84.
Winter J, Walker A, Shapiro D, et al. TPMT genotype: Is this a cost effective assay for patients about to begin azathioprine treatment for inflammatory bowel disease. Gut. 2004;53
85.
Derijks L, Gilissen L, Engels L, et al. 6-Mercaptopurine metabolites in patients with inflammatory bowel disease; Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. European collaboration: Towards drug development and rational drug therapy; 2003. p. 70.
86.
Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase) Pharmacogenetics. 2004 Mar;14(3):181–7. [PubMed: 15167706]
87.
Ansari AR, Marinaki T, Arenas M, et al. Mutation in the Itpa Gene Predicts Intolerance to Azathioprine. Dig Dis Week Abstr Itinerary Planner. 2003;2003
88.
Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. Gut. 2002;50 [PubMed: 11876691]
89.
Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998 Nov 1;129(9):716–8. [PubMed: 9841604]
90.
Black A, Capell H, McLeod H, et al. Do genetic polymorphism's influence the occurrence of azathioprine (AZA) toxicity in Rheumatic diseases. Br J Rheumatol. 1998;37
91.
Stolk JN, Boerbooms AM, De Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998 Oct;41(10):1858–66. [PubMed: 9778228]
92.
Stolk J, Boerbooms A, De Abreu R, et al. Are severe non-hematologic side-effects on azathioprine treatment caused by altered purine enzyme activities. Arthritis Rheum. 1996;39
93.
Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients.[see comment] Arch Dermatol. 1995 Feb;131(2):193–7. [PubMed: 7857117]
94.
Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Journal of Investigative Dermatology. 1994;102(4) [PubMed: 7857117]
95.
Kerstens PJ, Stolk JN, De Abreu RA, et al. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):142–5. [PubMed: 7818564]
96.
Kerstens P, Lambooy L, Boerbooms A, et al. Low levels of purine enzymes as a cause of azathioprine induced bone marrow toxicity in RA. Arthritis Rheum. 1992;35
97.
Walsh M, Royston C, Srinivas M, et al. Monitoring azathioprine (AZA) treatment in inflammatory bowel disease (IED): Rituals REvisited but not revised! Gastroenterol. 2008;134(4, Suppl 1)
98.
Walsh M, Royston C, Srinivas M, et al. Monitoring azathioprine treatment in inflammatory bowel disease: Rituals re-visited - But not revised! Gut. 2008;57(Suppl 1):A37–A38.
99.
Schmeling H, Abdelhaleem M, Benseler S, et al. Role of TPMT genotyping and azathioprine metabolites in predicting toxicity of azathioprine in PSLE patients. Arthritis Rheum. 2007;56(12):4265–6.
100.
Schmeling H, Abdelhaleem M, Benseler S, et al. Role of TPMT genotyping and azathioprine metabolites in predicting toxicity of azathioprine in pediatric SLE patients. Zeitschrift fuer Rheumatologie. 2007;66(7):641.
101.
Ansari AR, Soon S, Raoof S, et al. Pharmacogenetic profiling in azathioprine therapy: The role of TPMT, ITPA and MTHFR polymorphisms in drug toxicity. Gastroenterol. 2004;126
102.
Xin H, Fischer C, Schwab M, et al. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005 May 1;21(9):1105–9. [PubMed: 15854172]
103.
Xin HW, Fischer C, Schwab M, et al. Thiopurine S-methyltransferase as a target for drug interactions. Eur J Clin Pharmacol. 2005 Jul;61(5–6):395–8. [PubMed: 15952020]
104.
Gisbert JP, Gomollon F, Cara C, et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci. 2007 May;52(5):1262–9. [PubMed: 17334911]
105.
Dilger K, Schaeffeler E, Lukas M, et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit. 2007 Feb;29(1):1–5. [PubMed: 17304143]
106.
Zhang LR, Song DK, Zhang W, et al. Efficient screening method of the thiopurine methyltransferase polymorphisms for patients considering taking thiopurine drugs in a Chinese Han population in Henan Province (central China) Clinica Chimica Acta. 2007 Feb;376(1–2):45–51. [PubMed: 16952345]
107.
Oselin K, Anier K, Tamm R, et al. Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: reference values for Estonian population using HPLC-UV assay. Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences. 2006 Apr 13;834(1–2):77–83. [PubMed: 16517227]
108.
Khalil MN, Erb N, Khalil PN, et al. Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes.[erratum appears in J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1–2):348–50] Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences. 2005 Jul 5;821(1):105–11. [PubMed: 15897017]
109.
Heckmann JM, Lambson EM, Little F, et al. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neuro Sci. 2005 Apr 15;231(1–2):71–80. [PubMed: 15792824]
110.
Brouwer C, De Abreu RA, Keizer-Garritsen JJ, et al. Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. Eur J Cancer. 2005 Mar;41(4):613–23. [PubMed: 15737567]
111.
Hindorf U, Peterson C, Almer S. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit. 2004 Dec;26(6):673–8. [PubMed: 15570193]
112.
Ford LT, Cooper SC, Lewis MJ, et al. Reference intervals for thiopurine S-methyltransferase activity in red blood cells using 6-thioguanine as substrate and rapid non-extraction liquid chromatography.[see comment] Ann Clin Biochem. 2004 Jul;41(Pt 4):303–8. [PubMed: 15298742]
113.
Ganiere-Monteil C, Medard Y, Lejus C, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol. 2004 Apr;60(2):89–96. [PubMed: 15022030]
114.
Shipkova M, Niedmann PD, Armstrong VW, et al. Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem. 2004 Feb;50(2):438–41. [PubMed: 14752016]
115.
Indjova D, Shipkova M, Atanasova S, et al. Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. Ther Drug Monit. 2003 Oct;25(5):637–44. [PubMed: 14508388]
116.
Keizer-Garritsen JJ, Brouwer C, Lambooy LH, et al. Measurement of thiopurine S-methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children. Ann Clin Biochem. 2003 Jan;40(Pt 1):86–93. [PubMed: 12542916]
117.
Menor C, Fueyo J, Escribano O, et al. Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients. Mult Scler. 2002 May;8(3):243–8. [PubMed: 12120697]
118.
Anglicheau D, Sanquer S, Loriot MA, et al. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences. 2002 Jun 25;773(2):119–27. [PubMed: 12031837]
119.
Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.[see comment] Gastroenterol. 2002 Apr;122(4):904–15. [PubMed: 11910342]
120.
Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther. 2002 Jan;16(1):79–85. [PubMed: 11856081]
121.
Lennard L, Chew TS, Lilleyman JS. Human thiopurine methyltransferase activity varies with red blood cell age. British Journal of Clinical Pharmacology. 2001 Nov;52(5):539–46. [PMC free article: PMC2014613] [PubMed: 11736862]
122.
Alves S, Amorim A, Ferreira F, et al. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther. 2001 Aug;70(2):165–74. [PubMed: 11503011]
123.
Coulthard SA, Howell C, Robson J, et al. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood. 1998 Oct 15;92(8):2856–62. [PubMed: 9763570]
124.
Kroplin T, Weyer N, Gutsche S, et al. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol. 1998 May;54(3):265–71. [PubMed: 9681671]
125.
Micheli V, Jacomelli G, Fioravanti A, et al. Thiopurine methyltransferase activity in the erythrocytes of adults and children: and HPLC-linked assay. Clinica Chimica Acta. 1997 Mar 18;259(1–2):161–8. [PubMed: 9086303]
126.
Klemetsdal B, Straume B, Lysaa R, et al. Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol. 1995;48(6):495–9. [PubMed: 8582469]
127.
Lennard L, Singleton HJ. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. Journal of Chromatography B: Biomedical Applications. 1994 Nov 4;661(1):25–33. [PubMed: 7866549]
128.
Jacqz-Aigrain E, Bessa E, Medard Y, et al. Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors. British Journal of Clinical Pharmacology. 1994 Jul;38(1):1–8. [PMC free article: PMC1364830] [PubMed: 7946931]
129.
Chocair PR, Duley JA, Sabbaga E, et al. Fast and slow methylators: do racial differences influence risk of allograft rejection? Q J Med. 1993 Jun;86(6):359–63. [PubMed: 8171183]
130.
Szumlanski CL, Honchel R, Scott MC, et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992 Aug;2(4):148–59. [PubMed: 1306116]
131.
Tinel M, Berson A, Pessayre D, et al. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. British Journal of Clinical Pharmacology. 1991 Dec;32(6):729–34. [PMC free article: PMC1368554] [PubMed: 1768566]
132.
Woodson LC, Ames MM, Selassie CD, et al. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Molecular Pharmacology. 1983 Nov;24(3):471–8. [PubMed: 6633508]
133.
Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. Journal of Pharmacology & Experimental Therapeutics. 1982 Jul;222(1):174–81. [PubMed: 7086699]
134.
Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clinica Chimica Acta. 1978 May 2;85(3):323–33. [PubMed: 657528]
135.
Zhang B, Xu X, Zeng X, et al. Correlation of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration in Han Chinese patients treated with azathioprine 25 to 100 mg: A 1-year, single-center, prospective study. Curr Therap Res - Clin Experiment. 2006;67(4):270–82. [PMC free article: PMC3966017] [PubMed: 24678102]
136.
Lentz JJ, Cunnigham J, Winland M, et al. Performance evaluation of a thiopurine methyltransferase (TPMT) enzyme activity assay by reversed-phase HPLC. Am J Gastroenterol. 2000;95(9)
137.
Wong JL, Galloway T, Biggs L, et al. Assay of thiopurine methyltransferase (TPMT) for thiopurine therapy: The effect of storage on red blood cell TPMT activity. Gastroenterol. 2002;122(4 Suppl 1):A-222.
138.
Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009 Mar 15;29(6):654–61. [PubMed: 19183142]
139.
Schaeffeler E, Zanger UM, Eichelbaum M, et al. Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups.[see comment] Clin Chem. 2008 Oct;54(10):1637–47. [PubMed: 18687736]
140.
Haglund S, Taipalensuu J, Peterson C, et al. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. British Journal of Clinical Pharmacology. 2008 Jan;65(1):69–77. [PMC free article: PMC2291267] [PubMed: 17662091]
141.
Chowdhury J, Kagiala GV, Pushpakom S, et al. Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events. J Mol Diagn. 2007 Sep;9(4):521–9. [PMC free article: PMC1975104] [PubMed: 17690215]
142.
Ford L, Graham V, Berg J. Whole-blood thiopurine S-methyltransferase activity with genotype concordance: a new, simplified phenotyping assay. Ann Clin Biochem. 2006 Sep;43(Pt 5):354–60. [PubMed: 17036413]
143.
Indjova D, Atanasova S, Shipkova M, et al. Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the bulgarian population. Ther Drug Monit. 2003 Oct;25(5):631–6. [PubMed: 14508387]
144.
Dauer M, Schulze J, Loher F, et al. Determination of thiopurine S-methyltransferase phenotype using thin-layer chromatography and quantitative scanning. Eur J Clin Pharmacol. 2002 Apr;58(1):41–4. [PubMed: 11956672]
145.
Dervieux T, Medard Y, Verpillat P, et al. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. Leukemia. 2001 Nov;15(11):1706–12. [PubMed: 11681411]
146.
Menor C, Fueyo JA, Escribano O, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit. 2001 Oct;23(5):536–41. [PubMed: 11591900]
147.
Decaux G, Horsmans Y, Houssiau F, et al. High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am J Therapeut. 2001 May;8(3):147–50. [PubMed: 11344381]
148.
Coulthard SA, Rabello C, Robson J, et al. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol. 2000 Sep;110(3):599–604. [PubMed: 10997970]
149.
Alves S, Prata MJ, Ferreira F, et al. Screening of thiopurine S-methyltransferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat. 2000;15(3):246–53. [PubMed: 10679940]
150.
Ganiere-Monteil C, Pineau A, Kergueris MF, et al. Thiopurine methyl transferase activity: new extraction conditions for high-performance liquid chromatographic assay. Journal of Chromatography B: Biomedical Sciences & Applications. 1999 Apr 30;727(1–2):235–9. [PubMed: 10360443]
151.
Dervieux T, Medard Y, Baudouin V, et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. British Journal of Clinical Pharmacology. 1999 Dec;48(6):793–800. [PMC free article: PMC2014314] [PubMed: 10594482]
152.
Escousse A, Guedon F, Mounie J, et al. 6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype. J Pharm Pharmacol. 1998 Nov;50(11):1261–6. [PubMed: 9877312]
153.
Medard Y, Nafa S, Jacqz-Aigrain E. Thiopurine methyltransferase activity: new high-performance liquid chromatographic assay conditions. Journal of Chromatography. 1997 Oct 24 [PubMed: 9390740]
B, Biomedical Sciences & Applications. 700(1–2):275–7. [PubMed: 9390740]
154.
Lee EJ, Kalow W. Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther. 1993 Jul;54(1):28–33. [PubMed: 8330462]
155.
Johnson-Davis K, Juenke J, Pickering J, et al. An enzymatic assay used to identify patients with low thiopurine methyltransferase (TPMT) activity. Clin Chem. 2008;54
156.
Lindqvist M, Almer S, Hildebrand H, et al. Real time PCR methodology for quantification of thiopurine methyltransferase (TPMT) gene expression. Proceedings of the American Association for Cancer Research Annual Meeting. 2002;43:428–9.
157.
Stassen PM, Derks RP, Kallenberg CG, et al. Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects. Ann Rheum Dis. 2009 May;68(5):758–9. [PubMed: 19366895]
158.
Gardiner SJ, Gearry RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008 Jun;6(6):654–60. [PubMed: 18467186]
159.
Hindorf U, Lyrenas E, Nilsson A, et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol Suppl. 2004 Nov;39(11):1105–12. [PubMed: 15545169]
160.
Haglund S, Lindqvist M, Almer S, et al. Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease.[erratum appears in Clin Chem. 2004 Apr;50(4):788] Clin Chem. 2004 Feb;50(2):288–95. [PubMed: 14656901]
161.
Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002 Oct;16(10):1743–50. [PubMed: 12269967]
162.
Langley PG, Underhill J, Tredger JM, et al. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol. 2002 Oct;37(4):441–7. [PubMed: 12217596]
163.
Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.[see comment] Pharmacogenetics. 2002 Aug;12(6):429–36. [PubMed: 12172211]
164.
Daperno M, Canaparo R, Sostegni R, et al. Genotype and phenotype analysis of thiopurine-methyl-transferase (TPMT) in a northern Italian. Gastroenterol. 2008;134
165.
Allan M, Tendler D, Muir A, et al. Utility of thiopurine methyltransferase pharmacogenetic testing and monitoring of azathioprine metabolites in the management of autoimmune hepatitis. Gastroenterol. 2002;122
166.
Taylor E, Matsutani M, Barry M, et al. TPMT (thiopurine methyltransferase) genotype-phenotype accuracy in IBD patients. Gastroenterol. 2002;122(4 Suppl 1):A-222.
167.
Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol. 2010;52(1):106–11. [PubMed: 19906459]
168.
Vestergaard T, Bygum A. An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions. Clin Experiment Dermatol. 2010;35(2):140–4. [PubMed: 19663853]
169.
Banerjee S, Bishop WP. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.[see comment] J Pediatr Gastroenterol Nutr. 2006 Sep;43(3):324–30. [PubMed: 16954954]
170.
Bezier M, Reguiai Z, Vitry F, et al. Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases. European Journal of Dermatology. 2008 Sep;18(5):512–7. [PubMed: 18693152]
171.
Tamori A, Shinzaki M, Kosaka S, et al. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Internat. 2007 Feb;27(1):95–100. [PubMed: 17241387]
172.
De RL, Van Dieren JM, Van Deventer HJ, et al. Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1137–41. [PubMed: 16611274]
173.
Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006 Jan;4(1):44–9. [PubMed: 16431304]
174.
Jun JB, Cho DY, Kang C, et al. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clinical & Experimental Rheumatology. 2005 Nov;23(6):873–6. [PubMed: 16396707]
175.
Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol Suppl. 2003 Sep;38(9):972–7. [PubMed: 14531535]
176.
Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.[see comment] J Gastroenterol. 2003;38(8):740–6. [PubMed: 14505127]
177.
Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterol. 2000 Apr;118(4):705–13. [PubMed: 10734022]
178.
Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology. 1999 Jul;38(7):640–4. [PubMed: 10461478]
179.
Ishioka S, Hiyama K, Sato H, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese.[see comment] Internal Med. 1999 Dec;38(12):944–7. [PubMed: 10628931]
180.
Jojic N, Urosevic J, Bojic B, et al. Determination of thiopurine methyltransferase genotype in the patients with inflammatory bowel disease before and during azathioprine therapy. Arch Gastroenterohepatol. 2003;22(1–2):5–9.
181.
Kim JH, Cheon JH, Hong SS, et al. Can we predict highly frequent myelotoxicity during azathioprine/6-mercaptopurine treatment in Korean patients with inflammatory bowel disease by thiopurine methyltransferase genotyping and phenotyping or inosine triphosphate pyrophosphatase genotyping? A multicenter study. Gastroenterol. 2008;134
182.
Lopez AJ, Schwab M, Witt H, et al. The impact of genetic variants in TPMT, ITPA, MTHFR, SPINK1 and PRSS1 on azathioprine-induced pancreatitis. Gastroenterol. 2006;130
183.
Katsanos K, Ferrante M, Joossens M, et al. The MDR1 G2677T polymorphism is associated with gastrointestinal intolerance to azathioprine. Gastroenterol. 2006;130(4, Suppl 2):A199–A200.
184.
Curvers W, Derijks L, Stokkers P, et al. No Predictive Value of Tpmt Genotyping for Leukopenia Or Hepatotoxicity During Azathioprine Therapy in Inflammatory Bowel Disease. Dig Dis Week Abstr Itinerary Planner. 2003;2003
185.
Curvers W, Gilissen L, Derijks L, et al. Pharmacokinetic Analysis of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease. Dig Dis Week Abstr Itinerary Planner. 2003;2003
186.
Seddik M, Texier F, Ferrari N, et al. Thiopurine S-Methyltransferase Genotyping Does Not Predict Azathioprine-Induced Myelosuppression in Crohn'S Disease. Dig Dis Week Abstr Itinerary Planner. 2003;2003
187.
Qasim A, Molley C, McLoughlin R, et al. Absolute Leukocyte Count and Its Correlation with Thiopurine Methyl Transferase (Tpmt) Activity in Inflammatory Bowel Disease (Ibd) Patients Receiving Azathioprine (Aza)/6-Mercaptopurine (6Mp) Dig Dis Week Abstr Itinerary Planner. 2003;2003
188.
Rietdijk ST, Bartelsman J, Hommes DW, et al. Genetic polymorphisms of the thiopurine S-methyltransferase (TPMT) locus in patients treated with azathioprine for inflammatory bowel disease. Gastroenterol. 2001;120
189.
Shobowale-Bakre M, Hassan C, Ansari A, et al. Predicting drug toxicity and non-response: Azathioprine and thiopurine methyltransferase as a metabolic model. J Inherit Metabolic Dis. 2000;23
190.
Tani C, Mosca M, Colucci R, et al. Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases. Clin Experiment Rheum. 2009;27(2):321–4. [PubMed: 19473575]
191.
Kolorz M, Bartosova L, Hosek J, et al. Importance of thiopurine S-methyltransferase gene polymorphisms for prediction of azathioprine toxicity. Neuroendocrinol Let. 2009;30(Suppl1):137–42. [PubMed: 20027160]
192.
Shah JA, Edwards CM, Probert CS. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur J Gastroenterol Hepatol. 2008 Mar;20(3):169–73. [PubMed: 18301295]
193.
Firooz A, Ghandi N, Hallaji Z, et al. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Arch Dermatol. 2008 Sep;144(9):1143–7. [PubMed: 18794458]
194.
Kwan LY, Devlin SM, Mirocha JM, et al. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis. 2008 Jun;40(6):425–32. [PubMed: 18304898]
195.
Schedel J, Godde A, Schutz E, et al. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Ann N Y Acad Sci. 2006 Jun;1069:477–91. [PubMed: 16855176]
196.
Kader HA, Wenner WJ Jr, Telega GW, et al. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000 Jun;30(4):409–13. [PubMed: 10875470]
197.
Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989 Aug;46(2):149–54. [PubMed: 2758725]
198.
Gubanich P, Achkar DP, Lashner B, et al. Thiopurine methyl transferase (TPMT) phenotype as a predictor of clinical response and side effect profile in a population of IBD patients. Am J Gastroenterol. 2004;99(10, Suppl S):S269–S270.
199.
Domenech E, Garcia-Planella E, Fluvia L, et al. Clinical Implications of Thiopurine-Methyltransferase Activity (Tpmte) Induction by Azathioprine (Aza) Treatment in Patients with Inflammatory Bowel Disease (Ibd) Dig Dis Week Abstr Itinerary Planner. 2003;2003
200.
Wong JL, Lowes J, Biggs L, et al. The role of thiopurine methyltransferase (TPMT) activity assay before commencing thiopurine drugs in inflammatory bowel disease (IBD) Gastroenterol. 2002;122(4 Suppl 1):A-222.
201.
Moloney M, Langley P, McFarlane I. Azathioprine tolerance is related to TPMT activity in autoimmune hepatitis (AIH) Gastroenterol. 1997;112
202.
Stolk J, Boerbooms A, De Abreu R, et al. The predictive value of thiopurine-methyltransferase activity for the development of toxicity of azathioprine in the treatment of rheumatoid arthritis. Br J Rheumatol. 1997;36
203.
Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22(9):775–82. [PubMed: 16225485]
204.
Compagni A, Bartoli S, Buehrlen B, et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. [Review] [32 refs] Int J Technol Assess Health Care. 2008;24(3):294–302. [PubMed: 18601797]
205.
Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006;24(8):767–81. [PubMed: 16898847]
206.
Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct;100(10):2239–47. [PubMed: 16181376]
207.
Sayani FA, Prosser C, Bailey RJ, et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can J Gastroenterol. 2005 Mar;19(3):147–51. [PubMed: 15776134]
208.
Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology. 2004 Feb;43(2):156–63. [PubMed: 12923290]
209.
Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheum. 2002 Dec;29(12):2507–12. [PubMed: 12465143]
210.
Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol. 2000 Apr;42(4):628–32. [PubMed: 10727309]
211.
Gurwitz D, Rodriguez-Antona C, Payne K, et al. Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet. 2009 Aug;17(8):991–8. [PMC free article: PMC2986553] [PubMed: 19223932]
212.
Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: A pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125–32. [PubMed: 20066544]
213.
Schaeffeler E, Eichelbaum M, Reinisch W, et al. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat. 2006 2006 Sep;27(9):976. [PubMed: 16917910]
214.
Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Internal Med J. 2005 Oct;35(10):580–5. [PubMed: 16207256]
215.
Tsui NB. Multiple thiopurine S-methyltransferase variation detection: a step toward personalized medicine.[comment] Clin Chem. 2008 Oct;54(10):1598–9. [PubMed: 18824573]
216.
Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U.S.A. 1995 Feb 14;92(4):949–53. [PMC free article: PMC42614] [PubMed: 7862671]
217.
Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. [Review] [76 refs] Clin Chem. 2008 Nov;54(11):1770–9. [PubMed: 18801934]
218.
Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. [Review] [50 refs] Ther Drug Monit. 2004 Apr;26(2):231–5. [PubMed: 15228171]
219.
Kurzawski M, Dziewanowski K, Lener A, et al. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol. 2009 May;65(5):533–40. [PubMed: 19229528]
220.
Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44(6):750–9. [PubMed: 16729864]
221.
U.S.Food and Drug Administration. Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods; Approved Guideline. MM13-A. 2005;25(31)
222.
Fraser CG. Biological variation: from principles to practice. Washington D.C.: Amer Assn for Clinical Chemistry; 2001.
223.
The Federal Registrar. U.S. Department of Health and Human Services: Clinical Laboratory Improvement Amendments of 1988; Final Rules and Notice. 1992;57 42 CFR Part 493.
224.
Chen B, Gagnon M, Shahangian S, et al. Good laboratory practices for molecular genetic testing for heritable diseases and conditions. MMWR Recomm Rep. 2009 Jun 12;58(RR-6):1–37. [PubMed: 19521335]
225.
Grody W, Richards C. Molecular Diagnostic Methods for Genetic Disease; Approved Guideline. MM01-2A. 2006
226.
Wilson J, Zoccoli M, Jacobson J, et al. Verification and Validation of Multiplex Nucleic Acid Assays; Approved Guideline. MM17-A. 28(9):2008.
227.
Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. [Review] [153 refs] Eur J Clin Pharmacol. 2008 Aug;64(8):753–67. [PubMed: 18506437]
228.
Hamdan-Khalil R, Gala JL, Allorge D, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem Pharmacol. 2005 Feb 1;69(3):525–9. [PubMed: 15652243]
229.
Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol. 2008 Aug 1;76(3):404–15. [PubMed: 18602085]
230.
Lindqvist M, Skoglund K, Karlgren A, et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenet Genomics. 2007 Oct;17(10):891–5. [PubMed: 17885628]
231.
Kham SK, Soh CK, Liu TC, et al. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol. 2008 Apr;64(4):373–9. [PubMed: 18193212]
232.
Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?[see comment]. [Review] [80 refs] Ann Clin Biochem. 2004 Jul;41(Pt 4):294–302. [PubMed: 15298741]
233.
Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol. 2010;63(4):288–95. [PubMed: 20354201]
234.
Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007 Apr;32(2):187–95. [PubMed: 17381669]
235.
Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterol. 2000 Jun;118(6):1025–30. [PubMed: 10833476]
236.
Payne K, Newman WG, Gurwitz D, et al. TPMT testing in azathioprine: A 'cost-effective use of healthcare resources'? Personaliz Med. 2009;6(1):103–13.
237.
McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterol. 2002 Mar;122(3):838–9. [PubMed: 11878296]
238.
Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(Suppl 1):S30-8–S30-38. [PubMed: 12684587]
239.
Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol. 2003 May;36(5):390–5. [PubMed: 12702978]
240.
Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.[see comment] Clin Chem. 2007 Jul;53(7):1306–14. [PubMed: 17495015]
241.
Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol. 2004 Sep;99(9):1744–8. [PubMed: 15330913]
242.
Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001 Nov;29(3):306–9. [PubMed: 11600885]
243.
Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008 Jun;47(6):924–5. [PubMed: 16940305]
244.
Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004 Sep;53(Suppl 5):V1–16. [PMC free article: PMC1867788] [PubMed: 15306569]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.5M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...